Blends Are Not Studied. Their Ingredients Sometimes Are.
A combination product inherits neither the evidence nor the safety profile of its components. Almost no multi-peptide blend has been studied as a blend in humans.
Combination pharmacology is a discipline. Fixed-dose combinations in medicine are approved on their own trials, because two agents together can interact, compete or produce effects neither shows alone.
Blends discussed in research settings are typically assembled by convention rather than by trial. The named ratios circulate widely and rarely trace back to a published comparison of ratios.
Three specific unknowns
Stability in solution differs between peptides, so co-formulation raises questions about degradation that single-compound data cannot answer.
Attribution becomes impossible: if something changes, no one can say which component was responsible. And adverse-event profiles compound in ways that have not been characterised.
How our library handles them
Blend entries carry a preclinical grade regardless of how well studied an individual ingredient is, and each page states plainly that the blend itself has no human evidence base.
We link to the component entries so the underlying evidence can be read where it actually exists.
Research references
- Regulatory document
Regulatory considerations for fixed-dose combination products
This article is educational and is not medical advice. It does not recommend or provide individualised dosing. Speak with a qualified healthcare professional about your own health.